Anti-Human Angiopoietin-like Protein 3/ANGPTL3 Reference Antibody (Evinacumab, RUO) (HV176016)

Name: Anti-Human Angiopoietin-like Protein 3/ANGPTL3 Reference Antibody (Evinacumab, RUO)
Brand: abinScience
SKU: HV176016
Price: 176 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HV176016
Description	Evinacumab (HV176016) is a research-grade recombinant antibody targeting ANG-5. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG4-kappa
Expression system	Mammalian cells
Clonality	Monoclonal
Target	ANG-5, Angiopoietin-like protein 3, ANGPT5, Angiopoietin-5, ANGPTL3, Angiopoietin-related protein 3
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q9Y5C1
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	REGN1500, 1446419-85-7
Background	Angiopoietin-related protein 3 (ANGPTL3) is a ~53 kDa protein. Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism. Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake. Has a stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL activity. The inhibition of LPL activity appears to be an indirect mechanism involving recruitment of proprotein convertases PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from the cell surface; the function does not require ANGPTL3 proteolytic cleavage but seems to be mediated by the N-terminal domain, and is not inhibited by GPIHBP1. Can inhibit endothelial lipase, causing increased plasma levels of high density lipoprotein (HDL) cholesterol and phospholipids. 1. Koishi, R. et al. (2002) Nature genetics 30, 151-7. PMID: 11788823 2. Ono, M. et al. (2003) The Journal of biological chemistry 278, 41804-9. PMID: 12909640 3. Robciuc, MR. et al. (2013) Arteriosclerosis, thrombosis, and vascular biology 33, 1706-13. PMID: 23661675 4. Tikka, A. et al. (2014) Bioscience reports 34, e00160. PMID: 25495645 5. Shimizugawa, T. et al. (2002) The Journal of biological chemistry 277, 33742-8. PMID: 12097324 6. Lee, EC. et al. (2009) The Journal of biological chemistry 284, 13735-13745. PMID: 19318355 7. Liu, J. et al. (2010) The Journal of biological chemistry 285, 27561-70. PMID: 20581395 8. Shimamura, M. et al. (2007) Arteriosclerosis, thrombosis, and vascular biology 27, 366-72. PMID: 17110602 9. Shan, L. et al. (2009) The Journal of biological chemistry 284, 1419-24. PMID: 19028676 10. Shimamura, M. et al. (2003) Biochemical and biophysical research communications 301, 604-9. PMID: 12565906
Note	For research use only. Not suitable for clinical or therapeutic use.